Table 2.
Adjusted odds ratio (OR) of the probability of gametocyte prevalence, using a multivariate random effect logistic model for untreated and SP-treated children separately.
| Risk factors for gametocytaemia | Adjusted OR (95% CI) | ||
| No treatment | Treatment with SP | ||
| Day of follow-up | Day 7 | 1.48 (0.62 – 3.56)¥ | 1.77 (0.93–3.34)¥ |
| Day 14 | 1 (ref) | 1 (ref) | |
| Age | <5 years | 6.34 (1.15–34.90) | 5.38 (1.91–15.17) |
| 5–9 years | 3.07 (0.98–9.55)¥ | 3.22 (1.19–8.72) | |
| 10–16 years | 1 (ref) | 1 (ref) | |
| Asexual parasite density at enrolment | Per 100 parasites/μl | 1.05 (1.00–1.11) | 1.01 (1.00–1.01) |
| Gametocyte prevalence at enrolment | Present | 3.35 (1.22–9.18) | 4.12 (2.11–8.02) |
| Absent | 1 (ref) | 1 (ref) | |
| SP treatment outcome | R2/3 resistance | - | 3.40 (1.61–7.19) |
| Rl resistance | - | 1.06 (0.45–2.47)¥ | |
| Adequate response | - | 1 (ref) | |
Adjusted = adjusted for all other variables in the model, OR = odds ratio, CI = confidence interval, ref = reference group, ¥ = not statistically significant, - = not applicable. A GEE model was used to allow for correlation between observations from the same individuals. Children reporting the use of antimalarial drugs prior to enrolment were excluded from these analyses.